Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture–Derived Influenza Vaccine in Healthy Children and Adolescents Three to Seventeen Years of Age
Authors:
- Timo VesikariTVTimo Vesikari
- Stan L. BlockSBStan L. Block
- Fernando GuerraFGFernando Guerra
- Maria LattanziMLMaria Lattanzi
- Sandra HolmesSHSandra Holmes
- Allen IzuAIAllen Izu
- Nicolaos GaitatzisNGNicolaos Gaitatzis
- Anne Katrin HilbertAHAnne Katrin Hilbert
- Nicola GrothNGNicola Groth
- 1 May 2012
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 31 (5) , 494-500
Abstract
The safety and immunogenicity of the cell-culture-derived seasonal trivalent influenza vaccine ([CCIV]; Optaflu) has been reported previously in adults and the elderly. In this study, we compared the safety, reactogenicity and immunogenicity of CCIV with a conventional egg-derived trivalent influenza vaccine (TIV) in a healthy pediatric population. A total of 3604 subjects were randomized to receive 2 doses of CCIV or TIV (3-8 years, n = 2630) at a 28-day interval or a single vaccination (9-17 years, n = 974). Antibody levels on days 1, 29 and 50 were measured by hemaglutination inhibition assay using egg-derived and cell-derived test antigens. Adverse reactions were solicited via memory aids for 7 days after each injection, and unsolicited adverse events/serious adverse events were collected for 6 months postvaccination. Noninferiority of CCIV versus TIV was demonstrated for most immunogenicity measures, particularly by using cell-derived antigen in the hemaglutination inhibition assay. In 3- to 8-year-olds (the primary objective), both CCIV and TIV met all 3 Committee for Medicinal Products for Human Use immunogenicity criteria for A/H1N1 and A/H3N2 strains. Lower immune responses were observed against the B strain, fulfilling Committee for Medicinal Products for Human Use criteria only for geometric mean ratio (TIV, CCIV) and seroconversion rate (TIV, CCIV [cell-derived antigen]). Both CCIV and TIV were safe and well tolerated, with no differences in local and systemic solicited reactions or in unsolicited adverse events/serious adverse events. CCIV produced in mammalian cell culture is a safe, well-tolerated and immunogenic alternative to conventional egg-derived influenza vaccines for children and adolescents.Keywords
This publication has 17 references indexed in Scilit:
- A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccineVaccine, 2009
- Influenza Vaccine Manufacture: Keeping Up with ChangeThe Journal of Infectious Diseases, 2009
- Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United StatesAmerican Journal of Epidemiology, 2009
- Vero cell platform in vaccine production: moving towards cell culture-based viral vaccinesExpert Review of Vaccines, 2009
- The Underrecognized Burden of Influenza in Young ChildrenNew England Journal of Medicine, 2006
- Universal vaccination of children against influenza: Are there indirect benefits to the community?A systematic review of the evidenceVaccine, 2006
- Burden of Influenza in Children in the CommunityThe Journal of Infectious Diseases, 2004
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the United StatesJAMA, 2003
- The Japanese Experience with Vaccinating Schoolchildren against InfluenzaNew England Journal of Medicine, 2001